BNTCHIGH SIGNALFINANCIAL10-K

BNTC disclosed a material restatement of prior financial statements due to understated share-based compensation expenses caused by incorrect system configuration during a November 2023 data migration.

The company's acknowledgment that previously filed financial statements cannot be relied upon creates significant credibility concerns and potential regulatory scrutiny. While the errors were non-cash in nature and related to share-based compensation accounting, the material impact on reported results undermines confidence in the company's financial controls and reporting processes.

Comparing 2025-09-22 vs 2024-09-26View on EDGAR →
FINANCIAL ANALYSIS

BNTC's balance sheet strengthened substantially with cash and equivalents nearly doubling to $97.7M while total liabilities declined meaningfully, suggesting recent equity financing activity. However, operating performance deteriorated significantly with operating losses expanding substantially and revenue declining 42%. The combination of a much stronger cash position alongside worsening operational metrics indicates the company raised capital while burning through funds at an accelerated pace during its development activities.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+92.2%
$50.9M$97.7M

Cash position surged 92.2% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+90.8%
$52.2M$99.6M

Asset base grew 90.8% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+90.7%
$51.7M$98.5M

Current assets grew 90.7% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-89.9%
$179K$18K

Capex reduced 89.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
-85.7%
-$22.5M-$41.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-74.3%
-$21.8M-$37.9M

Net income declined 74.3% — review whether driven by operations, interest costs, or non-recurring items.

Current Liabilities
Balance Sheet
-63.4%
$4.9M$1.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-53.7%
$5.0M$2.3M

Liabilities reduced 53.7% — deleveraging improves balance sheet strength and financial flexibility.

Revenue
P&L
-42.2%
$102K$59K

Revenue declined 42.2% — significant demand weakness or market share loss warrants investigation.

Operating Cash Flow
Cash Flow
-21.6%
-$19.4M-$23.6M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2025-09-22
PRIOR — 2024-09-26
ADDED
s (the Company ) Annual Report on Form 10-K for the fiscal year ended June 30, 2025, the Company determined that in prior periods it had not appropriately recorded certain non-cash share-based compensation expenses.
As previously announced in the Current Report on Form 8-K filed with the U.S.
As a result of these misstatements, the Company is restating financial information for the Non-Reliance Periods.
All restated financial information for the Non-Reliance Periods is included in this Annual Report on Form 10-K and the Company has not filed, and does not intend to file, amendments to any of its filings that it has previously filed with the SEC.
Restatement Background The errors and corrective adjustments identified by the Company are non-cash in nature and resulted from the migration, in November 2023, of equity awards data to a new information recording system used to calculate the Company s share-based compensation expense, which was incorrectly configured resulting in understatements of share-based compensation expense, which in turn led to understatements of additional paid-in capital, accumulated deficit, net loss and loss per share.
+7 more — sign up free →
REMOVED
There were 10,555,728 shares of the Registrant s common stock, $0.0001 par value per share, outstanding on September 1 7 , 2024.
Certain Relationships and Related Transactions, and Director Independence III-2 Item 14.
On August 14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited.
The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life- threatening genetic disorder.
Our Strengths We believe that the combination of our proprietary ddRNAi and silence and replace technology, and our deep expertise in the design and development of genetic medicines, will enable us to achieve and maintain a leading position in gene silencing and gene therapy for the treatment of human disease.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →